2324 |
FMS RELATED TYROSINE KINASE 4 |
FLT4 |
FLT-4 |
FLT41 |
LMPH1A |
PCL |
VEGFR-3 |
VEGFR3 |
136352 |
3767 |
ENSG00000037280 |
OTTHUMG00000130931 |
VEGFR1/2/3 |
VEGFR |
VEGFR2/3 |
P35916 |
VGFR3_HUMAN |
PA28183 |
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 PRECURSOR (EC 2.7.1.112) (VEGFR-3) (TYROSINE-PROTEIN KINASE RECEPTOR FLT4). [SOURCE:UNIPROT/SWISSPROT;ACC:P35916] |
Tyrosine-protein kinase receptor FLT4 |
Fms-like tyrosine kinase 4 |
Vascular endothelial growth factor receptor 3 |
fms related receptor tyrosine kinase 4 |
T07303 |
1938 |
CHTD7 |
LMPHM1 |
Transmembrane Helix Count | 1 |
Target Subclass | Other |
Target Subclass | Kinase |
Target Main Class | Receptors |
Human Readable Name | DRUGGABLE GENOME |
CancerCommons Reported Gene Name | VEGF, PDGF |
Uniprot Status | Swiss-Prot |
Human Readable Name | KINASE |
Interpro Acc | IPR001245 |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Interpro Type | Domain |
Uniprot Evidence | 1: Evidence at protein level |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
n/a |
Trial Name | IMC-3C5 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Notes | |
Trial Name | AV-951 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | fruquintinib |
Novel drug target | Established target |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Notes | |
Mechanism of Interaction | Vascular endothelial growth factor receptor 3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Reported Cancer Type | Prostate |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Notes |
inhibitor (inhibitory) |
Trial Name | Vatalanib |
Novel drug target | Established target |
Trial Name | vatalanib, PTK 787 |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Notes | |
Novel drug target | Established target |
Trial Name | MGCD265 |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Notes | |
Trial Name | E7080 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor 3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | XL647 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor 3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor 3 inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
n/a |
Trial Name | Muparfostat |
Novel drug target | Established target |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | Pazopanib |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
n/a |
Novel drug target | Established target |
Trial Name | E-10030 |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Trial Name | Nexavar |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | cediranib, AZD2171,Recentin |
Notes |
inhibitor (inhibitory) |
Notes | |
Trial Name | Zactima |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | ENMD-2076 |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Trial Name | ABT-869, Linifanib |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Trial Name | dovitinib, TKI-258, CHIR-258 |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
FLT4 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
2324 | Entrez Gene Id |
FLT4 | Uniprot Gene Name |
VGFR3_HUMAN | Uniprot Id |
Uniprot Status | Swiss-Prot |
Human Readable Name | KINASE |
Interpro Acc | IPR001245 |
KINASE, DRUGGABLE GENOME |
ENSG00000037280 | Ensembl Gene Id |
FLT4 | Gene Symbol |
P35916 | Uniprot Accession |
Transmembrane Helix Count | 1 |
Target Subclass | Other |
Target Subclass | Kinase |
ENSG00000037280 | Ensembl Gene Id |
FLT4 | Display Id |
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 PRECURSOR (EC 2.7.1.112) (VEGFR-3) (TYROSINE-PROTEIN KINASE RECEPTOR FLT4). [SOURCE:UNIPROT/SWISSPROT;ACC:P35916] | Description |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
2324 | Entrez Gene ID |
CancerCommons Reported Gene Name | VEGF, PDGF |
FLT4 | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
PA28183 | PharmGKB ID |
2324 | Entrez Gene ID |
1938 | CIViC Gene ID |
FLT-4 | TTD Gene Abbreviation |
T07303 | TTD Target ID |
ENSG00000037280 | Gene Symbol |
FLT4 | Ensembl Id |
DRUGGABLE GENOME |
2324 | Entrez Gene Id |
FLT4 | MyCancerGenome Gene Symbol |
VEGFR1/2/3 | MyCancerGenome Reported Gene Name |
VEGFR-3 | Gene Symbol |
VEGFR3 | GENE_SYMBOL |
FLT4 | GENE_SYMBOL |
Vascular endothelial growth factor receptor 3 | UNIPROT |
FLT4 | Gene Symbol |
CLINICALLY ACTIONABLE |
2324 | Gene ID |
FLT41 | dGene Synonym |
LMPH1A | dGene Synonym |
KINASE, TYROSINE KINASE |
Vascular endothelial growth factor receptor 3 | Gene Name |
P35916 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |